Cargando…

Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection

INTRODUCTION: Fecal microbiota transplantation resolves recurrent Clostridium difficile infections in greater than 82% of patients. Highly screened, processed universal donor fecal material is available. We compared cost and scheduling efficiency of fecal microbiota transplantation by universal dono...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kyeong Ok, Schwartz, Margot A., Lin, Otto S. T., Chiorean, Michael V., Gluck, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822862/
https://www.ncbi.nlm.nih.gov/pubmed/31154629
http://dx.doi.org/10.1007/s12325-019-00974-x
_version_ 1783464424815722496
author Kim, Kyeong Ok
Schwartz, Margot A.
Lin, Otto S. T.
Chiorean, Michael V.
Gluck, Michael
author_facet Kim, Kyeong Ok
Schwartz, Margot A.
Lin, Otto S. T.
Chiorean, Michael V.
Gluck, Michael
author_sort Kim, Kyeong Ok
collection PubMed
description INTRODUCTION: Fecal microbiota transplantation resolves recurrent Clostridium difficile infections in greater than 82% of patients. Highly screened, processed universal donor fecal material is available. We compared cost and scheduling efficiency of fecal microbiota transplantation by universal donors to patient-directed donors. METHODS: Medical records from a prospectively maintained database of recurrent C. difficile patients who underwent fecal microbiota transplantation between 2012 and 2017 were reviewed retrospectively. Patient-directed donor stool was prepared in our microbiology laboratory using protocol-based screening. We transitioned to purchasing and using universal donor fecal material in 2015. Clinical outcomes, adverse events, time between consult to infusion, consultation fees, and material costs were compared. This was a retrospective comparison of two historical cohorts. RESULTS: A total of 111 fecal microbiota transplantations were performed on 105 patients (56 from patient-directed donors and 55 from universal donors). Median recipient age was 66 years (18–96) with male to female ratio of 1:2.7, equivalent in both cohorts. Total consultation fees were significantly lower in the universal donor group owing to fewer infectious disease consultations. Costs for donor screening and stool preparation were lower in the universal donor cohort ($485.0 vs. $1189.90 ± 541.4, p < 0.001, 95% CI 559.9–849.9). Time from consultations to infusion was shorter in the universal donor cohort (18.9 ± 19.1 vs. 36.4 ± 23.3 days, p < 0.001, 95% CI 9.521–25.591). Recurrences within 8 weeks after fecal microbiota transplantation were equivalent (p = 0.354). Adverse events were equivalent. CONCLUSIONS: Fecal microbiota transplantation using universal donors versus patient-directed donors for recurrent C. difficile showed comparable efficacy and short-term complications. The use of universal donors resulted in significant cost savings and scheduling efficiency.
format Online
Article
Text
id pubmed-6822862
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-68228622019-11-06 Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection Kim, Kyeong Ok Schwartz, Margot A. Lin, Otto S. T. Chiorean, Michael V. Gluck, Michael Adv Ther Original Research INTRODUCTION: Fecal microbiota transplantation resolves recurrent Clostridium difficile infections in greater than 82% of patients. Highly screened, processed universal donor fecal material is available. We compared cost and scheduling efficiency of fecal microbiota transplantation by universal donors to patient-directed donors. METHODS: Medical records from a prospectively maintained database of recurrent C. difficile patients who underwent fecal microbiota transplantation between 2012 and 2017 were reviewed retrospectively. Patient-directed donor stool was prepared in our microbiology laboratory using protocol-based screening. We transitioned to purchasing and using universal donor fecal material in 2015. Clinical outcomes, adverse events, time between consult to infusion, consultation fees, and material costs were compared. This was a retrospective comparison of two historical cohorts. RESULTS: A total of 111 fecal microbiota transplantations were performed on 105 patients (56 from patient-directed donors and 55 from universal donors). Median recipient age was 66 years (18–96) with male to female ratio of 1:2.7, equivalent in both cohorts. Total consultation fees were significantly lower in the universal donor group owing to fewer infectious disease consultations. Costs for donor screening and stool preparation were lower in the universal donor cohort ($485.0 vs. $1189.90 ± 541.4, p < 0.001, 95% CI 559.9–849.9). Time from consultations to infusion was shorter in the universal donor cohort (18.9 ± 19.1 vs. 36.4 ± 23.3 days, p < 0.001, 95% CI 9.521–25.591). Recurrences within 8 weeks after fecal microbiota transplantation were equivalent (p = 0.354). Adverse events were equivalent. CONCLUSIONS: Fecal microbiota transplantation using universal donors versus patient-directed donors for recurrent C. difficile showed comparable efficacy and short-term complications. The use of universal donors resulted in significant cost savings and scheduling efficiency. Springer Healthcare 2019-06-01 2019 /pmc/articles/PMC6822862/ /pubmed/31154629 http://dx.doi.org/10.1007/s12325-019-00974-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Kim, Kyeong Ok
Schwartz, Margot A.
Lin, Otto S. T.
Chiorean, Michael V.
Gluck, Michael
Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
title Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
title_full Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
title_fullStr Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
title_full_unstemmed Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
title_short Reducing Cost and Complexity of Fecal Microbiota Transplantation Using Universal Donors for Recurrent Clostridium difficile Infection
title_sort reducing cost and complexity of fecal microbiota transplantation using universal donors for recurrent clostridium difficile infection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822862/
https://www.ncbi.nlm.nih.gov/pubmed/31154629
http://dx.doi.org/10.1007/s12325-019-00974-x
work_keys_str_mv AT kimkyeongok reducingcostandcomplexityoffecalmicrobiotatransplantationusinguniversaldonorsforrecurrentclostridiumdifficileinfection
AT schwartzmargota reducingcostandcomplexityoffecalmicrobiotatransplantationusinguniversaldonorsforrecurrentclostridiumdifficileinfection
AT linottost reducingcostandcomplexityoffecalmicrobiotatransplantationusinguniversaldonorsforrecurrentclostridiumdifficileinfection
AT chioreanmichaelv reducingcostandcomplexityoffecalmicrobiotatransplantationusinguniversaldonorsforrecurrentclostridiumdifficileinfection
AT gluckmichael reducingcostandcomplexityoffecalmicrobiotatransplantationusinguniversaldonorsforrecurrentclostridiumdifficileinfection